Klasse PJ: The molecular basis of HIV entry. Cell Microbiol. 2012, 14: 1183-1192.
PubMed Central
CAS
PubMed
Google Scholar
Zwick MB, Burton DR: HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr HIV Res. 2007, 5: 608-624.
CAS
PubMed
Google Scholar
Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, Wyatt R, Sodroski J: Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol. 1997, 71: 9808-9812.
PubMed Central
CAS
PubMed
Google Scholar
Morikita T, Maeda Y, Fujii S, Matsushita S, Obaru K, Takatsuki K: The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism. AIDS Res Hum Retroviruses. 1997, 13: 1291-1299.
CAS
PubMed
Google Scholar
Stamatatos L, Cheng-Mayer C: An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol. 1998, 72: 7840-7845.
PubMed Central
CAS
PubMed
Google Scholar
Losman B, Bolmstedt A, Schonning K, Bjorndal A, Westin C, Fenyo EM, Olofsson S: Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. AIDS Res Hum Retroviruses. 2001, 17: 1067-1076.
CAS
PubMed
Google Scholar
Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC: The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol. 2004, 78: 5205-5215.
PubMed Central
CAS
PubMed
Google Scholar
Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, Zolla-Pazner S, Kayman SC: Antibodies That Are Cross-Reactive for Human Immunodeficiency Virus Type 1 Clade A and Clade B V3 Domains Are Common in Patient Sera from Cameroon, but Their Neutralization Activity Is Usually Restricted by Epitope Masking. J Virol. 2005, 79: 780-790.
PubMed Central
CAS
PubMed
Google Scholar
Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, Burke B, Cheng-Mayer C, Stamatatos L: The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol. 2005, 79: 9069-9080.
PubMed Central
CAS
PubMed
Google Scholar
Sagar M, Wu X, Lee S, Overbaugh J: Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol. 2006, 80: 9586-9598.
PubMed Central
CAS
PubMed
Google Scholar
Shibata J, Yoshimura K, Honda A, Koito A, Murakami T, Matsushita S: Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J Virol. 2007, 81: 3757-3768.
PubMed Central
CAS
PubMed
Google Scholar
Ching LK, Vlachogiannis G, Bosch KA, Stamatatos L: The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen. J Virol. 2008, 82: 949-956.
PubMed Central
CAS
PubMed
Google Scholar
Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, Ehlert AK, Regoes RR, Gunthard HF, Trkola A: Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med. 2011, 208: 1419-1433.
PubMed Central
CAS
PubMed
Google Scholar
Starcich BR, Hahn BH, Shaw GM, McNeely PD, Modrow S, Wolf H, Parks ES, Parks WP, Josephs SF, Gallo RC, Wong-Staal F: Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell. 1986, 45: 637-648.
CAS
PubMed
Google Scholar
Willey RL, Rutledge RA, Dias S, Folks T, Theodore T, Buckler CE, Martin MA: Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A. 1986, 83: 5038-5042.
PubMed Central
PubMed
Google Scholar
Hu G, Liu J, Taylor KA, Roux KH: Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J Virol. 2011, 85: 2741-2750.
PubMed Central
CAS
PubMed
Google Scholar
Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA: Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer. Science. 2013, 342: 1477-83.
CAS
PubMed
Google Scholar
Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB: Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer. Science. 2013, 342: 1484-90.
PubMed Central
CAS
PubMed
Google Scholar
Wyatt R, Sullivan N, Thali M, Repke H, Ho D, Robinson J, Posner M, Sodroski J: Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol. 1993, 67: 4557-4565.
PubMed Central
CAS
PubMed
Google Scholar
Stamatatos L, Wiskerchen M, Cheng-Mayer C: Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. AIDS Res Hum Retroviruses. 1998, 14: 1129-1139.
CAS
PubMed
Google Scholar
Groenink M, Fouchier RA, Broersen S, Baker CH, Koot M, van't Wout AB, Huisman HG, Miedema F, Tersmette M, Schuitemaker H: Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science. 1993, 260: 1513-1516.
CAS
PubMed
Google Scholar
Sullivan N, Thali M, Furman C, Ho DD, Sodroski J: Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol. 1993, 67: 3674-3679.
PubMed Central
CAS
PubMed
Google Scholar
Koito A, Harrowe G, Levy JA, Cheng-Mayer C: Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol. 1994, 68: 2253-2259.
PubMed Central
CAS
PubMed
Google Scholar
Palmer C, Balfe P, Fox D, May JC, Frederiksson R, Fenyo EM, McKeating JA: Functional characterization of the V1V2 region of human immunodeficiency virus type 1. Virology. 1996, 220: 436-449.
CAS
PubMed
Google Scholar
Toohey K, Wehrly K, Nishio J, Perryman S, Chesebro B: Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology. 1995, 213: 70-79.
CAS
PubMed
Google Scholar
Haim H, Strack B, Kassa A, Madani N, Wang L, Courter JR, Princiotto A, McGee K, Pacheco B, Seaman MS, Smith AB, Sodroski J: Contribution of Intrinsic Reactivity of the HIV-1 Envelope Glycoproteins to CD4-Independent Infection and Global Inhibitor Sensitivity. PLoS Pathog. 2011, 7: e1002101-
PubMed Central
CAS
PubMed
Google Scholar
Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, Schmidt SD, Stuckey J, Yang Y, Zhou T, Zhu J, Vicic DA, Debnath AK, Shapiro L, Bewley CA, Mascola JR, Sodroski JG, Kwong PD: Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A. 2012, 109: 5663-5668.
PubMed Central
CAS
PubMed
Google Scholar
Harrison SC: Viral membrane fusion. Nat Struct Mol Biol. 2008, 15: 690-698.
PubMed Central
CAS
PubMed
Google Scholar
Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, Wyatt R, Sodroski J, Doyle ML: Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A. 2000, 97: 9026-9031.
PubMed Central
CAS
PubMed
Google Scholar
Rao M, Peachman KK, Kim J, Gao G, Alving CR, Michael NL, Rao VB: HIV-1 Variable Loop 2 and its Importance in HIV-1 Infection and Vaccine Development. Curr HIV Res. 2013, 11: 427-438.
PubMed Central
CAS
PubMed
Google Scholar
Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR, Principal Investigators PG, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009, 326: 285-289.
PubMed Central
CAS
PubMed
Google Scholar
Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, et al: Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011, 85: 9998-10009.
PubMed Central
CAS
PubMed
Google Scholar
Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Principal Investigators PG, Koff WC, Wilson IA, Burton DR, Poignard P: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011, 477: 466-470.
PubMed Central
CAS
PubMed
Google Scholar
Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, Cohen S, Staudinger R, Zolla-Pazner S: Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol. 2005, 79: 5232-5237.
PubMed Central
CAS
PubMed
Google Scholar
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009, 361: 2209-2220.
CAS
PubMed
Google Scholar
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, et al: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012, 366: 1275-1286.
PubMed Central
CAS
PubMed
Google Scholar
Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, de Camp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, et al: Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012, 490: 417-420.
PubMed Central
CAS
PubMed
Google Scholar
Yates NL, Liao HX, Fong Y, de Camp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, et al: Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. Sci Transl Med. 2014, 6: 228ra239-
Google Scholar
Chackerian B, Rudensey LM, Overbaugh J: Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol. 1997, 71: 7719-7727.
PubMed Central
CAS
PubMed
Google Scholar
Fox DG, Balfe P, Palmer CP, May JC, Arnold C, McKeating JA: Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site. J Virol. 1997, 71: 759-765.
PubMed Central
CAS
PubMed
Google Scholar
Shioda T, Oka S, Xin X, Liu H, Harukuni R, Kurotani A, Fukushima M, Hasan MK, Shiino T, Takebe Y, Iwamoto A, Nagai Y: In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression. J Virol. 1997, 71: 4871-4881.
PubMed Central
CAS
PubMed
Google Scholar
Masciotra S, Owen SM, Rudolph D, Yang C, Wang B, Saksena N, Spira T, Dhawan S, Lal RB: Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression. AIDS. 2002, 16: 1887-1898.
CAS
PubMed
Google Scholar
Kitrinos KM, Hoffman NG, Nelson JA, Swanstrom R: Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J Virol. 2003, 77: 6811-6822.
PubMed Central
CAS
PubMed
Google Scholar
Harrington PR, Nelson JA, Kitrinos KM, Swanstrom R: Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection. J Virol. 2007, 81: 5413-5417.
PubMed Central
CAS
PubMed
Google Scholar
Bar KJ, Tsao CY, Iyer SS, Decker JM, Yang Y, Bonsignori M, Chen X, Hwang KK, Montefiori DC, Liao HX, Hraber P, Fischer W, Li H, Wang S, Sterrett S, Keele BF, Ganusov VV, Perelson AS, Korber BT, Georgiev I, McLellan JS, Pavlicek JW, Gao F, Haynes BF, Hahn BH, Kwong PD, Shaw GM: Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog. 2012, 8: e1002721-
PubMed Central
CAS
PubMed
Google Scholar
Curlin ME, Zioni R, Hawes SE, Liu Y, Deng W, Gottlieb GS, Zhu T, Mullins JI: HIV-1 envelope subregion length variation during disease progression. PLoS Pathog. 2010, 6: e1001228-
PubMed Central
CAS
PubMed
Google Scholar
Doria-Rose NA, Georgiev I, O'Dell S, Chuang GY, Staupe RP, McLellan JS, Gorman J, Pancera M, Bonsignori M, Haynes BF, Burton DR, Koff WC, Kwong PD, Mascola JR: A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies. J Virol. 2012, 86: 8319-8323.
PubMed Central
CAS
PubMed
Google Scholar
Moore PL, Sheward D, Nonyane M, Ranchobe N, Hermanus T, Gray ES, Abdool Karim SS, Williamson C, Morris L: Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol. 2013, 87: 4882-4894.
PubMed Central
CAS
PubMed
Google Scholar
Chen P, Hubner W, Spinelli MA, Chen BK: Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol. 2007, 81: 12582-12595.
PubMed Central
CAS
PubMed
Google Scholar
Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O: Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol. 2007, 81: 1000-1012.
PubMed Central
CAS
PubMed
Google Scholar
Sattentau Q: Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol. 2008, 6: 815-826.
CAS
PubMed
Google Scholar
Duncan CJ, Williams JP, Schiffner T, Gartner K, Ochsenbauer C, Kappes J, Russell RA, Frater J, Sattentau QJ: High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J Virol. 2014, 88: 2025-2034.
PubMed Central
PubMed
Google Scholar
Russell RA, Martin N, Mitar I, Jones E, Sattentau QJ: Multiple proviral integration events after virological synapse-mediated HIV-1 spread. Virology. 2013, 443: 143-149.
CAS
PubMed
Google Scholar
Del Portillo A, Tripodi J, Najfeld V, Wodarz D, Levy DN, Chen BK: Multiploid inheritance of HIV-1 during cell-to-cell infection. J Virol. 2011, 85: 7169-7176.
PubMed Central
CAS
PubMed
Google Scholar
Zhong P, Agosto LM, Munro JB, Mothes W: Cell-to-cell transmission of viruses. Curr Opin Virol. 2012, 3: 44-50.
PubMed Central
PubMed
Google Scholar
Zhong P, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, Derse D, Uchil PD, Heidecker G, Mothes W: Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS One. 2013, 8: e53138-
PubMed Central
CAS
PubMed
Google Scholar
Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D: Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature. 2011, 477: 95-98.
CAS
PubMed
Google Scholar
Abela IA, Berlinger L, Schanz M, Reynell L, Gunthard HF, Rusert P, Trkola A: Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 2012, 8: e1002634-
PubMed Central
CAS
PubMed
Google Scholar
Malbec M, Porrot F, Rua R, Horwitz J, Klein F, Halper-Stromberg A, Scheid JF, Eden C, Mouquet H, Nussenzweig MC, Schwartz O: Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J Exp Med. 2013, 210: 2813-21.
PubMed Central
CAS
PubMed
Google Scholar
Jolly C, Kashefi K, Hollinshead M, Sattentau QJ: HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med. 2004, 199: 283-293.
PubMed Central
CAS
PubMed
Google Scholar
O'Rourke SM, Schweighardt B, Phung P, Fonseca DP, Terry K, Wrin T, Sinangil F, Berman PW: Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J Virol. 2010, 84: 11200-11209.
PubMed Central
PubMed
Google Scholar
Mazurov D, Ilinskaya A, Heidecker G, Lloyd P, Derse D: Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS Pathog. 2010, 6: e1000788-
PubMed Central
PubMed
Google Scholar
Dale BM, Alvarez RA, Chen BK: Mechanisms of enhanced HIV spread through T-cell virological synapses. Immunol Rev. 2013, 251: 113-124.
PubMed
Google Scholar
Schiffner T, Sattentau QJ, Duncan CJ: Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. Vaccine. 2013, 31: 5789-5797.
CAS
PubMed
Google Scholar
Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR: Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol. 2003, 77: 642-658.
PubMed Central
CAS
PubMed
Google Scholar
Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L: Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol. 2011, 85: 3128-3141.
PubMed Central
CAS
PubMed
Google Scholar
Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S, Letvin NL, Karasavvas N, Yang ZY, Dai K, Pancera M, Gorman J, Wiehe K, Nicely NI, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, et al: Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2.Immunity 2013.,
Los Alamos HIV Database: HIV-1/SIVcpz env protein sequences curated alignment. 2011. ., [http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html]
Wu X, Changela A, O'Dell S, Schmidt SD, Pancera M, Yang Y, Zhang B, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Kwong PD, Mascola JR: Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies. J Virol. 2011, 85: 4578-4585.
PubMed Central
CAS
PubMed
Google Scholar
Ho SH, Tasca S, Shek L, Li A, Gettie A, Blanchard J, Boden D, Cheng-Mayer C: Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques. J Virol. 2007, 81: 8621-8633.
PubMed Central
CAS
PubMed
Google Scholar
Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL: Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013, 9: e1003738-
PubMed Central
PubMed
Google Scholar
Honnen WJ, Krachmarov C, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A: Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J Virol. 2007, 81: 1424-1432.
PubMed Central
CAS
PubMed
Google Scholar
Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD, Conrad TP, Lempicki RA, McLaughlin S, Pascuccio M, Gopaul R, McNally J, Cruz CC, Censoplano N, Chung E, Reitano KN, Kottilil S, Goode DJ, Fauci AS: HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008, 9: 301-309.
CAS
PubMed
Google Scholar
Cicala C, Arthos J, Fauci AS: HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med. 2011, 9 (Suppl 1): S2-
PubMed Central
CAS
PubMed
Google Scholar
Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, Salazar MG, Decker JM, Parrish EH, Berg A, Hopper J, Hora B, Kumar A, Mahlokozera T, Yuan S, Coleman C, Vermeulen M, Ding H, Ochsenbauer C, Tilton JC, Permar SR, Kappes JC, Betts MR, Busch MP, Gao F, Montefiori D, Haynes BF, Shaw GM, Hahn BH, Doms RW: Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog. 2012, 8: e1002686-
PubMed Central
CAS
PubMed
Google Scholar
Pauls E, Ballana E, Moncunill G, Bofill M, Clotet B, Ramo-Tello C, Este JA: Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. AIDS. 2009, 23: 266-268.
CAS
PubMed
Google Scholar
McLinden RJ, Labranche CC, Chenine AL, Polonis VR, Eller MA, Wieczorek L, Ochsenbauer C, Kappes JC, Perfetto S, Montefiori DC, Michael NL, Kim JH: Detection of HIV-1 neutralizing antibodies in a human CD4(+)/CXCR4(+)/CCR5(+) T-lymphoblastoid cell assay system. PLoS One. 2013, 8: e77756-
PubMed Central
PubMed
Google Scholar
Mayr LM, Cohen S, Spurrier B, Kong XP, Zolla-Pazner S: Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. PLoS One. 2013, 8: e70859-
PubMed Central
CAS
PubMed
Google Scholar
Spurrier B, Sampson J, Gorny MK, Zolla-Pazner S, Kong XP: Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV. J Virol. 2014, 88: 4100-4112.
PubMed Central
PubMed
Google Scholar
Chen BK: T cell virological synapses and HIV-1 pathogenesis. Immunol Res. 2012, 54: 133-139.
CAS
PubMed
Google Scholar
Murooka TT, Deruaz M, Marangoni F, Vrbanac VD, Seung E, von Andrian UH, Tager AM, Luster AD, Mempel TR: HIV-infected T cells are migratory vehicles for viral dissemination. Nature. 2012, 490: 283-287.
PubMed Central
CAS
PubMed
Google Scholar
McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, et al: Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011, 480: 336-343.
PubMed Central
CAS
PubMed
Google Scholar
Bunnik EM, Euler Z, Welkers MR, Boeser-Nunnink BD, Grijsen ML, Prins JM, Schuitemaker H: Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med. 2010, 16: 995-997.
CAS
PubMed
Google Scholar
Freed EO, Martin MA: Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol. 1994, 68: 2503-2512.
PubMed Central
CAS
PubMed
Google Scholar
Wang WK, Essex M, Lee TH: Single amino acid substitution in constant region 1 or 4 of gp120 causes the phenotype of a human immunodeficiency virus type 1 variant with mutations in hypervariable regions 1 and 2 to revert. J Virol. 1996, 70: 607-611.
PubMed Central
CAS
PubMed
Google Scholar
Carrillo A, Ratner L: Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J Virol. 1996, 70: 1310-1316.
PubMed Central
CAS
PubMed
Google Scholar
Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993, 67: 6642-6647.
PubMed Central
CAS
PubMed
Google Scholar
Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996, 70: 1100-1108.
PubMed Central
CAS
PubMed
Google Scholar
Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol. 1994, 68: 4821-4828.
PubMed Central
CAS
PubMed
Google Scholar
Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, Sodroski J: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol. 1993, 67: 3978-3988.
PubMed Central
CAS
PubMed
Google Scholar
Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK: The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res Hum Retroviruses. 2004, 20: 1254-1258.
CAS
PubMed
Google Scholar
Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC: Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009, 458: 636-640.
CAS
PubMed
Google Scholar
Wild C, Greenwell T, Matthews T: A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses. 1993, 9: 1051-1053.
CAS
PubMed
Google Scholar
Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002, 46: 1896-1905.
PubMed Central
CAS
PubMed
Google Scholar
Kueck T, Neil SJ: A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog. 2012, 8: e1002609-
PubMed Central
PubMed
Google Scholar
Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, Bandawe G, Mlisana K, Abdool Karim SS, Williamson C, Morris L: Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009, 5: e1000598-
PubMed Central
PubMed
Google Scholar
Bontjer I, Land A, Eggink D, Verkade E, Tuin K, Baldwin C, Pollakis G, Paxton WA, Braakman I, Berkhout B, Sanders RW: Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol. 2009, 83: 368-383.
PubMed Central
CAS
PubMed
Google Scholar
Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, Telenti A, Furrer H, Yerly S, Francioli P: Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol. 2010, 39: 1179-1189.
PubMed
Google Scholar
Rieder P, Joos B, von Wyl V, Kuster H, Grube C, Leemann C, Boni J, Yerly S, Klimkait T, Burgisser P, Weber R, Fischer M, Günthard HF: HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS. 2010, 24: 1177-1183.
PubMed
Google Scholar
Rusert P, Mann A, Huber M, von Wyl V, Gunthard HF, Trkola A: Divergent effects of cell environment on HIV entry inhibitor activity. AIDS. 2009, 23: 1319-1327.
CAS
PubMed
Google Scholar
Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D: Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 1997, 15: 871-875.
CAS
PubMed
Google Scholar
Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Niederost B, Weber R, Stiegler G, Katinger H, Günthard HF, Trkola A: In vivo and in vitro escape from neutralizing antibodies 2G12, 2 F5, and 4E10. J Virol. 2007, 81: 8793-8808.
PubMed Central
CAS
PubMed
Google Scholar
Agosto LM, Zhong P, Munro J, Mothes W: Highly Active Antiretroviral Therapies Are Effective against HIV-1 Cell-to-Cell Transmission. PLoS Pathog. 2014, 10: e1003982-
PubMed Central
PubMed
Google Scholar
Richardson MW, Carroll RG, Stremlau M, Korokhov N, Humeau LM, Silvestri G, Sodroski J, Riley JL: Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. J Virol. 2008, 82: 11117-11128.
PubMed Central
CAS
PubMed
Google Scholar